Yahoo Web Search

  1. Ads

    related to: tyrosine kinase inhibitors
    • GIST Resistance

      Learn more about the complexity of

      GIST and a treatment option.

    • Patient Education

      A patient and care partners guide

      with treatment information.

Search results

    • Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

      FOX 23 News Albany· 6 days ago

      ... data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's...

    • Small Business - Shelby County Reporter | Shelby County Reporter

      The Shelby County Reporter· 6 days ago

      Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic